Skip to main content

Dr. Rex is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
  • Read the latest clinical news, personalized to your specialty.

See Dr. Rex's full profile

Already have an account?

  • Office

    2617C W Holcombe Blvd
    Houston, TX 77025
    Phone+1 832-279-3107

Education & Training

  • National Institutes of Health Clinical Center
    National Institutes of Health Clinical CenterFellowship, Infectious Disease, 1987 - 1991
  • Stanford Health Care-Sponsored Stanford University
    Stanford Health Care-Sponsored Stanford UniversityResidency, Internal Medicine, 1984 - 1987
  • Baylor College of Medicine
    Baylor College of MedicineClass of 1982

Certifications & Licensure

  • CA State Medical License
    CA State Medical License 1986 - Present
  • TX State Medical License
    TX State Medical License 1985 - 2025
  • American Board of Internal Medicine Internal Medicine

Publications & Presentations

PubMed

Press Mentions

  • F2G Announces FDA Filing Acceptance of New Drug Application for Olorofim for the Treatment of Invasive Fungal Infections
    F2G Announces FDA Filing Acceptance of New Drug Application for Olorofim for the Treatment of Invasive Fungal InfectionsDecember 19th, 2022
  • F2G Announces Data from Phase 2b Study at ID Week 2022 Showing Positive Therapeutic Response in Patients with Invasive Fungal Infections Treated with Olorofim
    F2G Announces Data from Phase 2b Study at ID Week 2022 Showing Positive Therapeutic Response in Patients with Invasive Fungal Infections Treated with OlorofimOctober 21st, 2022
  • Results from Phase 2 THOR-2 Study Showed Improved Rates of Recurrence-Free Survival in Patients with High-Risk Non-Muscle-Invasive Bladder Cancer with Select Fibroblast Growth Factor Receptor Alterations Treated with Erdafitinib Versus Chemotherapy
    Results from Phase 2 THOR-2 Study Showed Improved Rates of Recurrence-Free Survival in Patients with High-Risk Non-Muscle-Invasive Bladder Cancer with Select Fibroblast Growth Factor Receptor Alterations Treated with Erdafitinib Versus ChemotherapyOctober 25th, 2023
  • Join now to see all